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A cancer immune signature implicating good prognosis
and responsiveness to immunotherapy was described that
is observed also in other aspects of immune-mediated, tis-
sue-specific destruction (TSD) [1,2]. Its determinism
remains, however, elusive. On one side it appears that the
genetic background of the host’s bears significantly on
immune responsiveness, on the other it appears that
tumor can behave differently within the same genetic
background (as in the case of mixed responses). This
apparent paradox can only be explained by a multi-factor-
ial model of cancer immune responsiveness [3]. It should
be emphasized that host and cancer genetics are largely
overlapping since cancer cells carry the majority of the
host’s genetics. Thus, inherited genetic factors may affect
the biology of cancer cells besides that of normal cells. It
could be postulated that some patients carry a genetic
background that make them resistant to immunotherapy
by effecting either the biology of the immune response,
the biology of the cancer cells or both. On the other hand,
“an immune-responsive genotype” may still be limited by
the genetics of the tumors: in other words, although the
patient may be predisposed to cancer rejection the tumor
lacks additional properties necessary for its recognition by
the immune response [4]. In this model, a favorable
genetic background of the host is necessary but not suffi-
cient for tumor rejection as the possession of a shotgun is
necessary to shoot a duck but at the same time a skill in
shooting is required. A good example is provided by the
analysis of patients with IRF-5 polymorphism [5]; the
“immune resistant phenotype” appears to almost exclu-
sively preclude cancer rejection during adoptive therapy
with tumor infiltrating lymphocytes; however, “the
immune responsive phenotype” can be segregated into
two categories; one enriched in patients responding to
therapy and the other of non-responding [6,7]. Although,
other host’s genetic factors could be responsible for this
sub-classification, it is also possible that, given a favorable
genetic background, the genetics of the tumor may
become the determining factor [8].
We recognize that this classification of factors that may
influence immune responsiveness may be too rigid. In rea-
lity, immune responsiveness may depend upon a conti-
nuum determined by the interaction of a multitude of
factors that for simplicity can be separated into broad
categories depending upon the host’s genetic background,
somatic mutations, and external factors such as intensity
and effectiveness of treatment, general condition of the
patient and a multitude of other hidden co-factors. In the
presentation at the NY Academy of Sciences we will pre-
sent our strategy to dissect the question of cancer immune
responsiveness by study dynamically the behavior of
human cancers under natural conditions on in response to
therapy.
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